Special to DG News NEW YORK, NY — May 19, 2002 —
Doctors who follow a logical drug algorithm in accordance with a study protocol achieve excellent blood pressure control in patients using an olmesartan medoxomil-based regimen, new findings suggest.
In fact, doctors in a clinical setting who adhered to such a regimen were able to obtain the widely recommended blood pressure goal of 140/90 mm Hg or less in most patients in their clinical practice, regardless of race, using olmesartan medoxomil, a new long-acting angiotensin receptor blocker, as their base therapy.
The results are from a study presented here Monday at the 17th Annual Scientific Meeting of the American Society of Hypertension (ASH) by Dr. Joel Neutel, with the Orange County Heart Institute and Research Center, Orange, California.
His group conducted an open-label, non-comparative trial during six four-week treatment periods at 21 sites. Eligible patients had a mean seated diastolic blood pressure of 90 mm Hg to 109 mm Hg. The co-primary end points were the percentage of subjects attaining a blood pressure goal of 140/90 mm Hg or less and the percentage attaining 130/85 mm Hg or less.
Following washout, 179 subjects received olmesartan medoxomil 20 mg/day for four weeks. At subsequent four-week intervals, treatment for subjects who had not attained the blood pressure goal of 130/85 mm Hg or less at each point was modified stepwise with titration of olmesartan medoxomil, addition of the diuretic hydrochlorothiazide, and titration of amlodipine. Subjects exited the study when they achieved the blood pressure goal of 130/85 mm Hg or less.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!